Get the Stockscreener App
0.6825
3.72%
-0.0264
After Hours:
.73
0.0475
+6.96%
Iterum Therapeutics Plc stock is traded at $0.6825, with a volume of 1.24M.
It is down -3.72% in the last 24 hours and down -11.71% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.7089
Open:
$0.72
24h Volume:
1.24M
Relative Volume:
1.58
Market Cap:
$32.19M
Revenue:
-
Net Income/Loss:
$-35.58M
P/E Ratio:
-0.2575
EPS:
-2.65
Net Cash Flow:
$-42.82M
1W Performance:
+0.63%
1M Performance:
-11.71%
6M Performance:
-50.54%
1Y Performance:
-38.51%
1-Day Range:
$0.64
$0.7348
1-Week Range:
$0.64
$0.7549
52-Week Range:
$0.6108
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.6825 | 31.01M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Signal strength of Iterum Therapeutics plc stock in tech scannersVolume Spike & Real-Time Volume Analysis Alerts - Newser
Is Iterum Therapeutics plc forming a bottoming baseEarnings Performance Report & Free Community Supported Trade Ideas - Newser
Applying Wyckoff theory to Iterum Therapeutics plc stockWeekly Investment Report & Verified Stock Trade Ideas - Newser
Will Iterum Therapeutics plc stock go up soonMarket Movement Recap & Technical Entry and Exit Tips - Newser
Combining price and volume data for Iterum Therapeutics plcIPO Watch & Weekly Chart Analysis and Trade Guides - Newser
How to read the order book for Iterum Therapeutics plcEarnings Growth Report & Free Expert Verified Stock Movement Alerts - Newser
Iterum Therapeutics plc stock outlook for YEARWeekly Investment Report & Safe Entry Point Identification - Newser
How to manage a losing position in Iterum Therapeutics plcWeekly Trading Summary & Risk Managed Investment Strategies - Newser
Institutional scanner results for Iterum Therapeutics plc2025 AllTime Highs & Consistent Return Investment Signals - Newser
Real time scanner hits for Iterum Therapeutics plc explainedJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Long term hold vs stop loss in Iterum Therapeutics plcWeekly Market Summary & Real-Time Market Sentiment Reports - Newser
Using R and stats models for Iterum Therapeutics plc forecastingCEO Change & Stock Market Timing Techniques - Newser
Ranking Iterum Therapeutics plc among high performing stocks via tools2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Published on: 2025-09-12 13:38:34 - Newser
Is Iterum Therapeutics plc still worth holding after the dip2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - Newser
Multi asset correlation models including Iterum Therapeutics plcJuly 2025 Short Interest & Entry Point Confirmation Alerts - Newser
Candlestick signals on Iterum Therapeutics plc stock todayIPO Watch & Long-Term Investment Growth Plans - Newser
Can momentum traders help lift Iterum Therapeutics plcJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
Iterum Therapeutics Faces Nasdaq Delisting Notice - MSN
Risk vs reward if holding onto Iterum Therapeutics plcJuly 2025 Levels & Weekly High Return Opportunities - Newser
Analyzing Iterum Therapeutics plc with risk reward ratio chartsJuly 2025 Drop Watch & Daily Market Momentum Tracking - Newser
Iterum Therapeutics plc stock chart pattern explainedIndex Update & AI Driven Stock Reports - Newser
Applying sector rotation models to Iterum Therapeutics plcPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
How institutional ownership impacts Iterum Therapeutics plc stockEarnings Growth Summary & Stock Portfolio Risk Control - Newser
Using data filters to optimize entry into Iterum Therapeutics plcMarket Growth Summary & Technical Pattern Based Signals - Newser
Iterum Therapeutics plc stock trend forecastTrade Volume Report & Reliable Volume Spike Trade Alerts - Newser
Iterum Therapeutics Faces Shareholder Pushback on Key Proposals - TipRanks
Iterum Therapeutics Launches New Antibiotic ORLYNVAH - MSN
What recovery options are there for Iterum Therapeutics plcWeekly Profit Report & Proven Capital Preservation Methods - Newser
Using Python tools to backtest Iterum Therapeutics plc strategies2025 Market Overview & Real-Time Volume Analysis Alerts - Newser
Measuring Iterum Therapeutics plc’s beta against major indicesWeekly Investment Summary & Accurate Trade Setup Notifications - Newser
Analyzing Iterum Therapeutics plc with multi timeframe chartsWeekly Investment Report & Growth Focused Stock Reports - Newser
Detecting support and resistance levels for Iterum Therapeutics plcAnalyst Downgrade & Consistent Profit Trade Alerts - Newser
What machine learning models say about Iterum Therapeutics plcWeekly Risk Report & Consistent Profit Alerts - Newser
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):